STOCK TITAN

AN2 Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags
conferences

Rhea-AI Summary

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company, announced that Eric Easom, President and CEO, will present at the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022. The on-demand presentation will be available starting September 12 at 7:00 A.M. E.T. Investors can access the webcast on the AN2 Therapeutics website, with an archived replay available for 30 days.

Loading...
Loading translation...
Argus Session date unavailable
-10.18% session move Open Argus
Details

News Market Reaction – ANTX

The recorded move for ANTX in the trading session of this news was -10.18%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

MENLO PARK, Calif., Aug. 29, 2022 (GLOBE NEWSWIRE) -- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced that Eric Easom, President and CEO will present at the H.C. Wainwright 24th Annual Global Investment Conference

Details of the event is as follows:

H.C. Wainwright 24th Annual Global Investment Conference, September 12-14, 2022

  • An on-demand presentation from Eric Easom, President and CEO will be available beginning Monday, September 12, 2022 at 7:00 A.M. E.T.

A webcast of the presentation can be accessed on the Investors section of the AN2 Therapeutics website at www.an2therapeutics.com. An archived replay will be available for at least 30 days following the presentation.

About AN2 Therapeutics, Inc.
AN2 Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. AN2 is developing epetraborole, a once-daily, oral treatment with a novel mechanism of action for patients with NTM lung disease, a rare, chronic, and progressive infectious disease caused by bacteria, known as mycobacteria, that leads to irreversible lung damage and can be fatal. For more information, please visit our website at www.an2therapeutics.com.

COMPANY CONTACT:
Lucy O. Day
Chief Financial Officer
l.day@an2therapeutics.com

INVESTOR AND MEDIA CONTACT: 
Anne Bowdidge 
ir@an2therapeutics.com


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is AN2 Therapeutics presenting at the H.C. Wainwright conference?

AN2 Therapeutics will have an on-demand presentation by Eric Easom, President and CEO, at the H.C. Wainwright 24th Annual Global Investment Conference.

When will the AN2 Therapeutics presentation be available?

The presentation will be available starting September 12, 2022, at 7:00 A.M. E.T.

Where can I watch the AN2 Therapeutics conference presentation?

The webcast of the presentation can be accessed on the Investors section of the AN2 Therapeutics website.

How long will the AN2 Therapeutics presentation be available for replay?

An archived replay of the presentation will be available for at least 30 days after the event.

What is the focus of AN2 Therapeutics?

AN2 Therapeutics focuses on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs.

Keep reading